Centro Médico Teknon
Centro Médico Teknon
Испания, Барселона
Bartolome Oliver
50 жылдар тәжірибе • 280+ емдеулер жасалған
аккредитациялар :
Аккредитация :
| Түркия | Австрия | Испания | |
| Кешенді емдеу нейробластома | бастап $28,000 | бастап $180,000 | бастап $70,000 |
Доктор Граупера — гематология және онкология бөлімін Барселонадағы SJD балалар ауруханасында (Еуропадағы ең үздік балалар емханаларының бірі) басқаратын, марапатқа ие болған балалар онкологы.
Балалар гематологиясы мен онкологиясы саласында 20 жылдан астам маманданған – доктор Лопес Ибор HM Montepríncipe емханасында балалар гематологиясы және онкологиясы бөлімшесін басқарады.
30 жылдан астам балалар онкологиясы саласында маманданған — доктор Лопес Ибор Мадридтегі HM Hospitales клиникасының Гематология және балалар онкологиясы бөлімшесін басқарады. Ол балалардағы қатерлі ісіктің ауыр түрлерін емдеуге ерекше көңіл бөледі.
Доктор Бартоломе Оливер 1979 жылдан бері жұмыс істеп келеді және микроскопиялық операцияларды жүзеге асырады, инвазивті емес радиохирургия аппараттарын пайдаланады. Ол онлайн консультациялар өткізеді және әртүрлі халықаралық медициналық қауымдастықтардың мүшесі болып табылады. Ол 150 жарияланымның және халықаралық медициналық конференцияларда 350 баяндаманың авторы.
Spain is home to internationally recognized pediatric oncology centers specializing in high-risk neuroblastoma care. SJD Barcelona Childrens Hospital is a global leader. It reports a 91.6% 3-year survival rate for patients in first remission. Other key institutions include Vall dHebron and Hospital Universitario HM Madrid.
Bookimed Expert Insight: While many large hospitals treat pediatric cancers, true specialization in neuroblastoma is concentrated in Barcelona and Madrid. SJD Barcelona Childrens Hospital manages over 450,000 patients annually and belongs to the top three European centers for pediatric oncology. Dr. Jaume Mora at SJD is highly sought after for protocols that avoid high-dose chemotherapy. If you need advanced molecular diagnostics or CAR NK cell therapy, these specific Spanish hubs are your best choice due to their high volume of over 5,000 pediatric procedures yearly.
Patient Consensus: Patients note it is vital to choose centers in Madrid or Barcelona where neuroblastoma volume is highest. Families emphasize confirming if the hospital manages entire treatment cycles including surgery and stem-cell backup under one roof.
Spain hosts world-renowned pediatric oncologists specializing in high-risk neuroblastoma. Key leaders include Dr. Jaume Mora Graupera at SJD Barcelona and Dr. Blanca Lopez Ibor at HM Madrid. These specialists utilize advanced molecular testing and anti-GD2 immunotherapy within JCI-accredited facilities.
Bookimed Expert Insight: Spain is a global leader for neuroblastoma, ranking 2nd in our medical destination data. While most seek famous names, our data shows institutional capacity matters most. SJD Barcelona serves 450,000 yearly patients, providing the high-volume experience necessary for complex relapsed cases.
Patient Consensus: Parents recommend finding a multidisciplinary team rather than one physician. They suggest asking how many neuroblastoma cases the lead doctor handles annually to ensure proficiency in managing high-risk disease.
Spain provides full access to advanced anti-GD2 immunotherapies for high-risk neuroblastoma. European Medicines Agency (EMA) approved drugs like Dinutuximab Beta are standard care protocols. Specialized centers in Barcelona and Madrid also provide next-generation therapies like Naxitamab under strict regulatory frameworks.
Bookimed Expert Insight: SJD Barcelona Children's Hospital managed 450,000 patient visits annually and serves as a global leader. Their protocol for Naxitamab is uniquely designed for low-toxicity. This is vital because anti-GD2 infusions typically require intensive pain management. Choosing a center with these specific specialized nursing teams significantly improves your child's comfort during the process.
Patient Consensus: Parents emphasize that access to these therapies depends on being at a major tertiary center. They recommend asking if the hospital routinely manages high-risk cases with anti-GD2 before starting treatment.
International patients can access neuroblastoma clinical trials in Spain. The country is a leading European research hub. It participates in major consortia like the International Society of Paediatric Oncology. Centers often offer early-phase trials and targeted anti-GD2 immunotherapy for high-risk or relapsed cases.
Bookimed Expert Insight: While SJD Barcelona Children's Hospital is a global leader performing 14,000 operations annually, Quironsalud Madrid offers a unique advantage for international families. Their protocol explicitly allows eligible patients to participate in clinical trials for free. This is a vital differentiator as many centers only cover the study drug while charging for standard hospital stays and diagnostics.
Patient Consensus: Families emphasize that logistics are often harder than meeting medical eligibility. Success requires coordinating frequent imaging, lab monitoring, and long stays in Spain while managing language barriers and non-study medical costs.
To obtain a medical second opinion in Spain, submit comprehensive medical records including pathology and imaging to JCI-accredited clinics. International departments coordinate remote video consultations or documentary reviews. Specialist oncologists typically provide a written report validating diagnosis or treatment plans for complex conditions like neuroblastoma.
Bookimed Expert Insight: Spain ranks highly for complex pediatric oncology because top centers integrate specialized molecular medicine laboratories. SJD Barcelona Children's Hospital handles 450,000 patients annually and uses dedicated research labs to refine neuroblastoma staging. For the most accurate second opinion, choose clinics with multidisciplinary teams that include pediatric radiologists and molecular pathologists.
Patient Consensus: Patients note it is essential to provide high-quality medical translations to avoid delays. Many emphasize that having a written report is vital for coordinating care with their home oncology team.